Wafa Malik – Page 2

ROS1 fusion-positive lung cancer

March 8, 2021April 12, 2021 Wafa MalikpublicationsLeave a Comment

Lin JJ*, Choudhury NJ*, Yoda S*, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN*, Drilon A*, Gainor JF*. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 Mar 8. doi: 10.1158/1078-0432.CCR-21-0032. Epub ahead of print. PMID: 33685866.

June 1, 2020June 11, 2020 Wafa MaliknewsLeave a Comment

While we were shut down, we said good-bye to Li, Pranav, Eunice, and Yi. Best wishes to all of you in your future endeavors – we will miss you!

June 1, 2020June 19, 2020 Wafa MaliknewsLeave a Comment

The lab is back open! We have been given the approval to restart our experiments while following strict social distancing and safety measures outlined by the hospital.

April 13, 2020June 11, 2020 Wafa MaliknewsLeave a Comment

We are continuing our science on-line – lab meetings, journal clubs, book club, data analysis, and project planning all via Zoom.

Congratulations to Dr. Chendi Li

April 9, 2020April 13, 2021 Wafa MaliknewsLeave a Comment

Congratulations to Chendi for receiving a Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Fellowship from the NCI to study targeted therapies for KRAS mutant lung cancer!

Level 4 workers

April 1, 2020June 12, 2020 Wafa MaliknewsLeave a Comment

A big thanks to Chelsi, Naveed and Satoshi who are maintaining our patient-derived cell cultures and PDX models during the shutdown.

March 20, 2020June 11, 2020 Wafa MaliknewsLeave a Comment

Due to COVID-19, we have had to temporarily shut down the lab. Please stay safe and healthy everyone!

Pharmacol Ther – March 2020

March 6, 2020June 3, 2020 Wafa MalikpublicationsLeave a Comment

Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. Pharmacol Ther. 2020 Jun;210:107522. doi: 10.1016/j.pharmthera.2020.107522. Epub 2020 Mar 6. PMID: 32151666.

Cancer Research- Feb 2020 PMID: 32086345

February 21, 2020April 12, 2021 Wafa MalikpublicationsLeave a Comment

Dagogo-Jack I*, Yoda S*, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY, Chin E, Do A, Marble HD, Stevens SE, Digumarthy SR, Saxena A, Nagy RJ, Benes CH, Azzoli CG, Lawrence MS, Gainor JF, Shaw AT*, Hata AN*. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 Jun 1;26(11):2535-2545. doi: 10.1158/1078-0432.CCR-19-3906. Epub 2020 Feb 21. PMID: 32086345.

Nat Biotechnol- April 2020 PMID: 32042168

February 10, 2020June 3, 2020 Wafa MalikpublicationsLeave a Comment

Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 Apr;38(4):420-425. doi: 10.1038/s41587-019-0404-8. Epub 2020 Feb 10. PMID: 32042168.

Author: Wafa Malik